TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14629842

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (osteopathic knee care and education only)
Number of subjects: 24
Study: 11127493

Group type: EXPERIMENTAL
Intervention: Swine dust exposure for 3 hours
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bronchial histamine challenge
Number of subjects: 17
Study: 9059094

Group type: EXPERIMENTAL
Intervention: Pulse oximeter readings in patients with low systemic vascular resistance
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pulse oximeter readings in patients with normal or high systemic vascular resistance
Number of subjects: 80
Study: 8363169

Group type: EXPERIMENTAL
Intervention: Single daily dose of amikacin (20 mg/kg) and ceftriaxone (30 mg/kg for adults, 80 mg/kg for children)
Number of subjects: 677

Group type: COMPARATOR
Intervention: Multiple daily doses of amikacin (6.5 mg/kg every 8 hours) and ceftazidime (33 mg/kg every 8 hours)
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Single daily dose of amikacin and ceftriaxone
Number of subjects: 677

Group type: COMPARATOR
Intervention: Multiple daily doses of amikacin and ceftazidime
Number of subjects: 677
Study: 3539037

Group type: EXPERIMENTAL
Intervention: Gold therapy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: D-penicillamine therapy (DPA)
Number of subjects: 72
Study: 30552272

Group type: EXPERIMENTAL
Intervention: Informed Shared Decision-Making Programme (ISDM-P)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Standard DMP care
Number of subjects: 279
Study: 26440470

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Biolimus A9-eluting stent (BES)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control vessel
Number of subjects: 22
Study: 23180285

Group type: EXPERIMENTAL
Intervention: 4-session mindfulness group intervention
Number of subjects: 114

Group type: COMPARATOR
Intervention: Minimal mindfulness self-help control group
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 4-session mindfulness group intervention (for patients younger than 60 years)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Minimal mindfulness self-help control group (for patients younger than 60 years)
Number of subjects: 114
Study: 22868684

Group type: EXPERIMENTAL
Intervention: Nalfurafine hydrochloride (5 µg/day)
Number of subjects: 211
Study: 20358154

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (MgSO4)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) after failed MgSO4 therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Intravenous magnesium sulphate (MgSO4) after failed iNO therapy
Number of subjects: 25
Study: 18553228

Group type: EXPERIMENTAL
Intervention: S-1 and docetaxel combination (Treatment Arm A)
Number of subjects: 628

Group type: COMPARATOR
Intervention: S-1 only (Treatment Arm B)
Number of subjects: 628
Study: 16122471

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Crystalloid cardioplegia
Number of subjects: 30
Study: 12423984

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (100 mg twice daily orally for 3 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 10712712

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine with ketamine 0.5 mg.kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.25% bupivacaine with ketamine 0.5 mg.kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 8626113

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone (cisplatin and bleomycin)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Chemotherapy plus whole pelvic radiation therapy (RT)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both regimens (Chemotherapy alone and Chemotherapy plus RT)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 89
Study: 1907963

Group type: EXPERIMENTAL
Intervention: Bupropion (225-450 mg/day)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Fluoxetine (20-80 mg/day)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 123
Study: 6626921

Group type: EXPERIMENTAL
Intervention: Return to full working duties 21 days after operation (Group A)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Return to light duties 21 days after operation and to full duties at 3 months (Group B)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Return to work immediately (Group C)
Number of subjects: 97

Group type: COMPARATOR
Intervention: No advice (Group D)
Number of subjects: 97
Study: 31239200

Group type: EXPERIMENTAL
Intervention: Blephadex™ Eyelid Wipes (used on treated eyes once daily for 30 days)
Number of subjects: 20
Study: 27807617

Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplements (ONS) administered until 12 weeks after discharge
Number of subjects: 113

Group type: COMPARATOR
Intervention: Usual postoperative diet (Control)
Number of subjects: 113
Study: 26809652

Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy with oral vinorelbine (60-80 mg/m² days 1 and 8) + cisplatin (80 mg/m² day 1) q3w
Number of subjects: 201

Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy with oral vinorelbine and cisplatin
Number of subjects: 201
Study: 24745197

Group type: EXPERIMENTAL
Intervention: Aversive leadership
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Directive leadership
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transactional leadership
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Person-focused leadership
Number of subjects: 0
Study: 21091403

Group type: EXPERIMENTAL
Intervention: Baseline hearing loss prevention training, follow-up toolbox (TB) reinforcement trainings, and use of a personal noise level indicator (NLI)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Toolbox (TB) reinforcement trainings and use of a personal noise level indicator (NLI)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Baseline training only
Number of subjects: 176
Study: 19916203

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha‐2b (1.5 microg/kg/week) and ribavirin (1000‐1200 mg/day orally)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha‐2b and ribavirin
Number of subjects: 110

Group type: COMPARATOR
Intervention: Interferon alpha‐2b (6 MIU, three times/week) and ribavirin
Number of subjects: 110

Group type: COMPARATOR
Intervention: Interferon alpha‐2b and ribavirin
Number of subjects: 110
Study: 17533961

Group type: EXPERIMENTAL
Intervention: Moderate dementia scenario
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Severe dementia scenario
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Community residents
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Care professionals
Number of subjects: 476
Study: 15527186

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 300

Group type: COMPARATOR
Intervention: No treatment, sham acupuncture, or standard treatment
Number of subjects: 300
Study: 11602811

Group type: EXPERIMENTAL
Intervention: Ciprofibrate (100 mg/d)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ciprofibrate + Aspirin (100 mg/d)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Aspirin (100 mg/d)
Number of subjects: 23
Study: 9838246

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 8076919

Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 253

Group type: COMPARATOR
Intervention: Sham-therapy
Number of subjects: 253
Study: 2739343

Group type: EXPERIMENTAL
Intervention: Mineral supplementation with 0.4 mmol calcium gluconate and 0.2 mmol glucose-1-phosphate/dl human milk
Number of subjects: 23

Group type: COMPARATOR
Intervention: No mineral supplementation
Number of subjects: 23
Study: 31392337

Group type: COMPARATOR
Intervention: 0.40 mg Cr/kg diet (2× the approved level)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: 2.0 mg Cr/kg diet (10× the approved level)
Number of subjects: 216
Study: 28481416

Group type: EXPERIMENTAL
Intervention: Blood flow restricted exercise (BFR) at 100 mmHg, 20% 1RM to concentric failure (BFRE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-load exercise (LLE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-load exercise (HLE) at 70% 1RM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood flow restricted exercise (BFR)
Number of subjects: 0
Study: 26615448

Group type: EXPERIMENTAL
Intervention: Inhaled epinephrine (4 mg/mL solution administered during mean 18 min)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intramuscular epinephrine (0.3 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 9
Study: 24344941

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once daily for 12 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Insulin glargine as add-on therapy (n=17)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 28
Study: 21251993

Group type: EXPERIMENTAL
Intervention: ICS 400 group
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: ICS 800 group
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: ICS 800 with vit D group
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (montelukast)
Number of subjects: 96
Study: 18425538

Group type: EXPERIMENTAL
Intervention: 30 mL 0.25% levobupivacaine and 40 mg methylprednisolone before wound closure
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 30 mL 0.25% levobupivacaine alone before closure
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 30 mL 0.25% levobupivacaine and 40 mg methylprednisolone before incision
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 30 mL 0.25% levobupivacaine alone before incision
Number of subjects: 100

Group type: COMPARATOR
Intervention: 30 mL 0.9% NaCl before wound closure
Number of subjects: 100
Study: 16528504

Group type: EXPERIMENTAL
Intervention: BrainLAB Kolibri navigation system
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 70
Study: 12491025

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg) + THC (30 mg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: THC (0, 15, 30 mg) with active naltrexone (50 mg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: THC (0, 15, 30 mg) with placebo naltrexone
Number of subjects: 39

Group type: COMPARATOR
Intervention: Methadone (5, 10 mg)
Number of subjects: 39
Study: 11140433

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) - oral (5 to 40 mg), inhaled (500 to 2000 microg), intravenous (250 to 1000 g)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 122
Study: 8865055

Group type: EXPERIMENTAL
Intervention: Moderate-dose lidocaine (3 mg/kg)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Low-dose lidocaine (1.5 mg/kg)
Number of subjects: 283
Study: 1531469

Group type: EXPERIMENTAL
Intervention: Intratubal injection of methotrexate (MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 7019761

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31078124

Group type: EXPERIMENTAL
Intervention: Dental pattern analysis system with treatment chronology on panoramic radiography
Number of subjects: 500
Study: 27739188

Group type: EXPERIMENTAL
Intervention: Bupropion (BUP; 4 × 150 mg)
Number of subjects: 9
Study: 25858408

Group type: EXPERIMENTAL
Intervention: Watching cartoons during immunisation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard distraction techniques during immunisation
Number of subjects: 35
Study: 23557110

Group type: EXPERIMENTAL
Intervention: Glucose infusion (10% glucose, 2.5 mL/kg/h)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Glucose-insulin infusion (10% glucose added 30 IU NovoRapid® per litre, 2.5 mL/kg/h)
Number of subjects: 11

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 11
Study: 21427153

Group type: EXPERIMENTAL
Intervention: Gait trainer assisted walking exercises
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional physical therapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 19070855

Group type: EXPERIMENTAL
Intervention: Medication management training for CMHPs
Number of subjects: 95

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 95
Study: 17390690

Group type: EXPERIMENTAL
Intervention: Haloperidol (10 microg x kg(-1))
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Droperidol (10 microg x kg(-1))
Number of subjects: 75

Group type: COMPARATOR
Intervention: Physiologic saline solution (Control)
Number of subjects: 75
Study: 14993509

Group type: EXPERIMENTAL
Intervention: Intraperitoneal tinzaparin (low‐molecular weight heparin) administered once a day for 3 months
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 11888531

Group type: COMPARATOR
Intervention: Diet protocol (20 kcal per kg fat‐free mass (FFM); 55% carbohydrates, 30% fat, and 15% proteins)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Malabsorptive surgery (biliopancreatic diversion)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Diet protocol
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Malabsorptive surgery
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Diet protocol and Malabsorptive surgery
Number of subjects: 79
Study: 9650015

Group type: EXPERIMENTAL
Intervention: Soybean oil meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mixed meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cream meal
Number of subjects: 10
Study: 8587293

Group type: COMPARATOR
Intervention: 2 g MMF daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 g MMF daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard regimen of cyclosporine and prednisone
Number of subjects: 0
Study: 2568816

Group type: EXPERIMENTAL
Intervention: High-osmolar contrast media (meglumine diatrizoate 76, 2100 mOsm/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-osmolar contrast media (iopamidol 370, 832 mOsm/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control period (baseline measurements before CM injection)
Number of subjects: 40
Study: 579125

Group type: EXPERIMENTAL
Intervention: Etofenamate (Rheumon Gel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0
Study: 31391001

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μ/kg over 10 min, pre-operatively)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (0.9% saline infusion)
Number of subjects: 90
Study: 28187952

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H7N1 vaccine (3.75 or 7.5μg hemagglutinin with AS03A or AS03B)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Unadjuvanted H7N1 vaccine (15μg hemagglutinin)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Adjuvanted groups
Number of subjects: 420
Study: 25628308

Group type: EXPERIMENTAL
Intervention: Heart failure with preserved ejection fraction
Number of subjects: 3487

Group type: COMPARATOR
Intervention: Heart failure with reduced ejection fraction
Number of subjects: 3487

Group type: COMPARATOR
Intervention: Degree of left ventricular systolic dysfunction (LVSD)
Number of subjects: 3487

Group type: COMPARATOR
Intervention: New York Heart Association class
Number of subjects: 3487
Study: 23324131

Group type: EXPERIMENTAL
Intervention: pemetrexed 500 mg/m² + cisplatin 75 mg/m² IV every 21 days × 3 cycles, followed by surgery and hemithoracic radiation (54 Gy)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: pemetrexed plus cisplatin followed by surgery and hemithoracic radiation (50.4 Gy after protocol amendment)
Number of subjects: 54
Study: 21677899

Group type: EXPERIMENTAL
Intervention: GEn 1200 mg
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: GEn 600 mg
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study: 19353317

Group type: EXPERIMENTAL
Intervention: Dynamic Condylar Screw (DCS)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Retrograde Intramedullary Supracondylar Nail (RIMSN)
Number of subjects: 68
Study: 17803667

Group type: EXPERIMENTAL
Intervention: ORS with probiotic powder containing 60 million cells of Lactobacillus rhamnosus GG (LGG)
Number of subjects: 646

Group type: COMPARATOR
Intervention: ORS alone
Number of subjects: 646
Study: 15148493

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G‐CSF)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Granulocyte-macrophage colony-stimulating factor (GM‐CSF)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both G‐CSF and GM‐CSF
Number of subjects: 72
Study: 12200890

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 0
Study: 9830189

Group type: EXPERIMENTAL
Intervention: Alternative benzodiazepine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antihistamines as substitute hypnotics
Number of subjects: 0
Study: 7924173

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 2528926

Group type: EXPERIMENTAL
Intervention: 1.0 micrograms/kg sufentanil
Number of subjects: 62

Group type: COMPARATOR
Intervention: 0.5 micrograms/kg sufentanil
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 1.5 micrograms/kg sufentanil
Number of subjects: 62
Study: 838241

Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study: 30876450

Group type: EXPERIMENTAL
Intervention: Flexible video endoscope
Number of subjects: 174

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 174
Study: 29357033

Group type: EXPERIMENTAL
Intervention: Resveratrol 800 mg/day for 2 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 26978782

Group type: EXPERIMENTAL
Intervention: Progressive inspiratory threshold loading
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 28
Study: 25017249

Group type: EXPERIMENTAL
Intervention: Prostate cancer dietary index score
Number of subjects: 13011

Group type: EXPERIMENTAL
Intervention: Adherence to recommendations to increase plant foods
Number of subjects: 13011

Group type: EXPERIMENTAL
Intervention: Adherence to tomato products
Number of subjects: 13011

Group type: EXPERIMENTAL
Intervention: WCRF/AICR index score
Number of subjects: 13011
Study: 23091850

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 30

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 30
Study: 20951282

Group type: COMPARATOR
Intervention: Working length determined by working length radiograph (Group 1)
Number of subjects: 84
Study: 17486065

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 100
Study: 16029678

Group type: EXPERIMENTAL
Intervention: 10% green tea cream and 300 mg twice‐daily green tea oral supplementation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo regimen
Number of subjects: 40
Study: 11916197

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Endoscopic variceal band ligation (VBL)
Number of subjects: 54
Study: 10191238

Group type: EXPERIMENTAL
Intervention: Reinfection group (previously infected with 35000HP)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (naive subjects)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study: 7595849

Group type: EXPERIMENTAL
Intervention: Excision of hernial sac/processus vaginalis (total of 236 hernial sacs)
Number of subjects: 798

Group type: COMPARATOR
Intervention: Distal splitting of hernial sac/processus vaginalis (total of 595 residual hernial sacs)
Number of subjects: 798
Study: 2336525

Group type: EXPERIMENTAL
Intervention: Nasometry
Number of subjects: 15

Group type: COMPARATOR
Intervention: Active anterior rhinomanometry
Number of subjects: 15
Study: 598301

Group type: EXPERIMENTAL
Intervention: 0.24 g i.v. Theophylline-ethylenediamine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.72 g infusion over four hours
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.36 g i.m. injection
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.72 g infusion over 6-8 hours
Number of subjects: 45
Study: 28198783

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Training (MCT group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT group)
Number of subjects: 20
Study: 30230204

Group type: EXPERIMENTAL
Intervention: Long-term administration of human albumin (20 g twice per week)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard medical care (SOC)
Number of subjects: 70
Study: 27161901

Group type: EXPERIMENTAL
Intervention: Metformin plus rosiglitazone
Number of subjects: 595

Group type: COMPARATOR
Intervention: Metformin plus lifestyle intervention
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Weight changes across treatment arms
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Weight change of ≥ 7% in overweight
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Full TODAY sample weight changes
Number of subjects: 595
Study: 25962383

Group type: EXPERIMENTAL
Intervention: Soybean oil (SO) lipid emulsion
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) lipid emulsion
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal saline (C)
Number of subjects: 42
Study: 23563184

Group type: EXPERIMENTAL
Intervention: Native smartphone application
Number of subjects: 24

Group type: COMPARATOR
Intervention: SMS text-only implementation
Number of subjects: 24